Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-742001 is a synthetic small-molecule diketo acid inhibitor of the influenza A virus PA endonuclease, an essential metal-dependent endonuclease subdomain of the viral RNA-dependent RNA polymerase complex that mediates “cap-snatching” from host pre-mRNAs to prime viral mRNA synthesis.[3][4][6][8] By chelating the two-metal catalytic core and engaging multiple residues within the PA endonuclease active site, L-742001 potently inhibits endonuclease activity (IC50 ~0.5 μM) and reduces influenza A viral replication in cell culture and in mouse models, establishing this chemotype as a prototype scaffold for influenza endonuclease-targeted antivirals.[3][4][6][8] Originally discovered in the 1990s and reported by Merck as an early RNA polymerase/PA inhibitor lead, L-742001 showed strong antiviral activity but was ultimately deemed unsuitable for further clinical development; however, its structural and resistance profiles have been widely used to map PA active-site interactions and guide the design of newer influenza endonuclease inhibitors.[3][6][8][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-742001.